CytomX Therapeutics, Inc.
CTMX
$2.03
$0.031.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -100.65% | 24.63% | 229.08% | 187.79% | -147.38% |
| Total Depreciation and Amortization | -9.87% | -6.78% | -3.73% | -6.54% | -1.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.71% | 16.59% | 25.07% | 24.36% | 41.48% |
| Change in Net Operating Assets | 61.99% | -14.79% | -44.44% | -92.28% | 63.88% |
| Cash from Operations | 25.14% | -5.70% | 3.96% | -6.04% | 24.94% |
| Capital Expenditure | 77.31% | -48.75% | -321.05% | 80.21% | 16.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -348.52% | 101.87% | -16.34% | -15.83% | -51.98% |
| Cash from Investing | -349.58% | 102.15% | -16.69% | -15.54% | -52.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 2,830.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -100.00% | 2,830.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.96% | 478.49% | 1.44% | -136.26% | -62.86% |